RAD51 and esophageal squamous cell carcinoma: In the current study, docetaxel, cisplatin and fluorouracil combination chemotherapy has been demonstrated to have activity in advanced and recurrent ESCC.50 Cetuximab may also have activity in ESCC.51,52 Rad51 targeted therapies may represent another novel therapeutic strategy.